- Home
- ASBPW
as 03-12-2025 1:31pm EST
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tract.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Aspire Biopharma Holdings Inc. Warrant News
ASBPW Breaking Stock News: Dive into ASBPW Ticker-Specific Updates for Smart Investing
Newsfile
a day ago
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation
ACCESS Newswire
9 days ago
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
ACCESS Newswire
15 days ago
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
ACCESS Newswire
20 days ago
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
Compare ASBPW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASBPW Aspire Biopharma Holdings Inc. Warrant - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.